Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma

Launched by WEST CHINA HOSPITAL · Apr 22, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different surgical methods for treating a type of liver cancer called hepatocellular carcinoma. The researchers want to compare traditional open surgery, which requires a larger incision, to a newer technique called laparoscopic surgery, which uses smaller cuts and may help patients recover faster. They aim to find out if there are differences in recovery and overall outcomes between these two surgical approaches, especially in terms of patient survival.

To participate in this trial, individuals must be at least 18 years old and have liver cancer that is only located in the right side of the liver. They should also have good liver function before the surgery. However, those with certain other types of liver cancers, previous major abdominal surgeries, or complications that might affect the surgery won’t be eligible. Participants can expect to receive either type of surgery, and their progress will be carefully monitored to gather important information about which method works best.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old;
• • 2. The lesion is limited to the right half of the liver and diagnosed as hepatocellular carcinoma based on paraffin pathology and immunohistochemistry results;
• • 3. The type of surgery is elective surgery;
• • 4. The patient's preoperative liver function was Child Pugh A or B grade, and the preoperative ASA (American Society of Anesthesiologists) rating was I, II, or III.
• Exclusion Criteria:
• • 1. Pathological confirmed cholangiocarcinoma, mixed cell carcinoma, or extrahepatic metastatic malignant tumors;
• • 2. Previous history of upper abdominal surgery;
• • 3. Simultaneously undergoing adjacent abdominal organ resection, major vessel and biliary reconstruction surgery, except for the gallbladder;
• • 4. Merge adjacent organ invasions except for the gallbladder, with main blood vessels, bile duct cancer emboli, or distant metastases;
• • 5. Lost to follow-up or loss of primary clinical data.